Patient characteristics according to response to rituximab treatment
| Characteristics . | NR (N = 10) . | PR (N = 11) . | CR (N = 8) . | All (N = 29) . |
|---|---|---|---|---|
| Sex (M/F) | 8/2 | 6/5 | 5/3 | 19/10 |
| Age (y) | 50 ± 9.4 | 59 ± 14.3 | 53 ± 5.7 | 54 ± 11.1 |
| Pathology | ||||
| FSC | 6 | 4 | 5 | 15 |
| FM | 3 | 6 | 2 | 11 |
| FLC | 1 | 1 | 1 | 3 |
| Average no. of prior chemotherapy courses | 2.40 | 2.55 | 2.13 | 2.38 |
| Prior transplantation | 1 | 3 | 1 | 5 |
| Bulky disease | 5 | 5 | 2 | 12 |
| Time between diagnosis and treatment (mo) | 63 ± 35 | 73 ± 39 | 69 ± 51 | 68 ± 40 |
| Estimated tumor cells* in biopsied samples (%) | 99, 97, 98, 96, 83, 98, 98, 93, 95, 97 | 87, 97, 94, 99, 99, 95, 95, 99, 89, 99, 74 | 76, 98, 94, 96, 91, 82, 75, 90 |
| Characteristics . | NR (N = 10) . | PR (N = 11) . | CR (N = 8) . | All (N = 29) . |
|---|---|---|---|---|
| Sex (M/F) | 8/2 | 6/5 | 5/3 | 19/10 |
| Age (y) | 50 ± 9.4 | 59 ± 14.3 | 53 ± 5.7 | 54 ± 11.1 |
| Pathology | ||||
| FSC | 6 | 4 | 5 | 15 |
| FM | 3 | 6 | 2 | 11 |
| FLC | 1 | 1 | 1 | 3 |
| Average no. of prior chemotherapy courses | 2.40 | 2.55 | 2.13 | 2.38 |
| Prior transplantation | 1 | 3 | 1 | 5 |
| Bulky disease | 5 | 5 | 2 | 12 |
| Time between diagnosis and treatment (mo) | 63 ± 35 | 73 ± 39 | 69 ± 51 | 68 ± 40 |
| Estimated tumor cells* in biopsied samples (%) | 99, 97, 98, 96, 83, 98, 98, 93, 95, 97 | 87, 97, 94, 99, 99, 95, 95, 99, 89, 99, 74 | 76, 98, 94, 96, 91, 82, 75, 90 |
FSC indicates follicular small cleaved; FM, follicular mixed; FLC, follicular large cell.
Plus-minus values are means ± SD.
Calculation described in “Materials and methods.”